Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 133,900 shares, an increase of 9.8% from the September 15th total of 122,000 shares. Based on an average trading volume of 32,600 shares, the short-interest ratio is presently 4.1 days. Approximately 0.7% of the company’s shares are sold short.

Dyadic International Trading Down 1.7 %

NASDAQ:DYAI traded down $0.02 during midday trading on Thursday, hitting $1.14. 22,175 shares of the company traded hands, compared to its average volume of 50,747. Dyadic International has a 12-month low of $0.93 and a 12-month high of $2.67. The company has a current ratio of 5.39, a quick ratio of 5.39 and a debt-to-equity ratio of 1.72. The firm’s fifty day moving average is $1.23 and its 200-day moving average is $1.50. The firm has a market capitalization of $33.33 million, a P/E ratio of -4.07 and a beta of 0.73.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Dyadic International had a negative return on equity of 145.95% and a negative net margin of 428.86%. The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same period in the prior year, the business posted ($0.07) earnings per share. On average, sell-side analysts predict that Dyadic International will post -0.26 EPS for the current year.

Institutional Trading of Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. Callan Capital LLC acquired a new position in Dyadic International, Inc. (NASDAQ:DYAI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned approximately 0.09% of Dyadic International as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 27.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Dyadic International in a research note on Monday, July 8th.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.